CASI Pharmaceuticals (CASI) News Today $7.04 -0.46 (-6.13%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$6.10▼$8.3650-Day Range$2.62▼$7.5052-Week Range$1.45▼$8.36Volume268,287 shsAverage VolumeN/AMarket Capitalization$93.77 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineCASI Pharmaceuticals (NASDAQ:CASI) Earns Hold Rating from Analysts at StockNews.comamericanbankingnews.com - December 7 at 1:22 AMHC Wainwright & Co. Maintains Buy Rating for CASI Pharmaceuticals: Here's What You Need To Knowmarkets.businessinsider.com - November 15 at 1:58 PMCASI Pharmaceuticals Posts Narrower Loss In Q3markets.businessinsider.com - November 14 at 10:21 AMCASI Pharmaceuticals GAAP EPS of -$0.35, revenue of $8.84Mmsn.com - November 14 at 10:21 AMCASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 BUSINESS AND FINANCIAL UPDATESfinance.yahoo.com - November 14 at 10:21 AMCASI : Juventas' CNCT 19 Approved In China For R/R B-cell Acute Lymphoblastic Leukemia Treatmentmarkets.businessinsider.com - November 8 at 8:33 AMH.C. Wainwright Sticks to Its Buy Rating for CASI Pharmaceuticals (CASI)markets.businessinsider.com - August 14 at 9:43 AMCASI Pharmaceuticals, Inc. Q2 Loss Widensmarkets.businessinsider.com - August 11 at 6:11 PMCASI Pharmaceuticals GAAP EPS of -$0.77, revenue of $9.82Mmsn.com - August 11 at 6:11 PMCASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATESfinance.yahoo.com - August 11 at 6:11 PMIonis Pharmaceuticals (IONS) Q2 Earnings and Revenues Surpass Estimates (Revised)msn.com - August 10 at 5:10 PMProPhase Labs, Inc. (PRPH) Reports Q2 Loss, Lags Revenue Estimatesmsn.com - August 10 at 11:06 AMMundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticalsfinance.yahoo.com - August 1 at 7:28 PMCleave Therapeutics Announces Acquisition of Clinical and Preclinical Assetsfinance.yahoo.com - July 20 at 8:35 AMCASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339finance.yahoo.com - July 20 at 8:35 AMSwitch Therapeutics Appoints Douglas Fambrough, Ph.D., to Board of Directorsfinance.yahoo.com - July 10 at 8:11 AMCASI - CASI Pharmaceuticals, Inc.finance.yahoo.com - June 28 at 8:27 PMWe Think CASI Pharmaceuticals (NASDAQ:CASI) Needs To Drive Business Growth Carefullyfinance.yahoo.com - May 28 at 10:37 AMCASI Pharmaceuticals, Inc. Announces First Quarter 2023 Financial Resultsfinanznachrichten.de - May 17 at 8:52 AMCASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTSfinance.yahoo.com - May 17 at 8:52 AMAnalysts Offer Insights on Healthcare Companies: Aurinia Pharmaceuticals (AUPH) and Cytosorbents (CTSO)markets.businessinsider.com - May 3 at 7:26 AMCASI Pharmaceuticals GAAP EPS of -$3.01 misses by $2.64, revenue of $43.12M beats by $32.31Mmsn.com - April 26 at 2:43 PMCASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022finance.yahoo.com - April 26 at 2:43 PMCASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTSfinance.yahoo.com - April 26 at 9:42 AMImproved Revenues Required Before CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Stock's 114% Jump Looks Justifiedfinance.yahoo.com - April 17 at 7:37 AMWill CASI Pharmaceuticals Inc (CASI) Outperform the Rest of the Stocks in the Healthcare Sector?benzinga.com - April 12 at 10:40 PMLisinopril Market Top Players and Forecast till 2031marketwatch.com - March 23 at 9:16 AMCASI Pharmaceuticals, Inc. Completes Redomiciliation Mergerfinanznachrichten.de - March 22 at 7:48 AMHypoxia Inducible Factor 1 Alpha Inhibitor Market Size 2023 Research Report by Growth Rate Analysis and Forecast till 2027marketwatch.com - March 17 at 7:51 PMTumor Necrosis Factor Inhibitors Market Size 2023 - 2030: About its Application, Qrganization Size, Sales Volume, and Regional Outlookmarketwatch.com - March 13 at 7:21 AMFoghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue Estimatesmsn.com - March 9 at 5:57 PMBTIG Reaffirms Their Hold Rating on MEI Pharma (MEIP)markets.businessinsider.com - February 14 at 7:10 AMA CASI Pharmaceuticals, Inc. (NASDAQ:CASI) insider increased their holdings by 16% last yearfinance.yahoo.com - February 6 at 10:25 AMH.C. Wainwright Keeps Their Buy Rating on Verastem (VSTM)markets.businessinsider.com - January 30 at 8:48 AMMarginal Zone B-cell Lymphoma Drugs Market Size, Outlook, Share, Prominent Players, Growth, and Forecast 2029marketwatch.com - January 18 at 9:50 AMCASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE MYELOMA IN CHINAfinance.yahoo.com - January 6 at 9:20 AMCasi Pharmaceuticals to run clinical trial for multiple myeloma drug in Chinafinance.yahoo.com - January 6 at 9:20 AMAnalysis of Ibritumomab Tiuxetan Market for the Period 2023 to 2028 : Development, Growth and Key Factorsmarketwatch.com - January 5 at 7:57 AMChinese pharmas and biotechs risk of delisting averted as US regulators review auditsmsn.com - December 16 at 6:42 PMCASI PHARMACEUTICALS' PARTNER JUVENTAS ANNOUNCES NEW DRUG APPLICATION FOR CNCT19 ACCEPTED BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATIONfinance.yahoo.com - December 15 at 7:39 AMCASI Pharmaceuticals Third Quarter 2022 Earnings: Beats Expectationsfinance.yahoo.com - November 17 at 6:50 AMCASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTSfinance.yahoo.com - November 14 at 11:05 AMCASI Pharmaceuticals, Inc. (CASI) Reports Q3 Loss, Lags Revenue Estimatesfinance.yahoo.com - November 14 at 11:05 AMScynexis (SCYX) Reports Q3 Loss, Misses Revenue Estimatesnasdaq.com - November 9 at 11:30 AMCasi Pharmaceuticalsforbes.com - October 7 at 3:52 PMCASI Pharmaceuticals Exits Juventas Biotechnology Investmentmarketwatch.com - September 23 at 8:42 AMCASI PHARMACEUTICALS ANNOUNCES EXIT OF JUVENTAS INVESTMENT TO STRENGTHEN BALANCE SHEETfinance.yahoo.com - September 23 at 8:42 AMCASI Pharmaceuticals Earnings Perspective: Return On Capital Employedmsn.com - September 9 at 10:50 AMWednesday 9/7 Insider Buying Report: JELD, CASInasdaq.com - September 7 at 6:02 PMCASI PHARMACEUTICALS AND BIOINVENT ANNOUNCE DOSING OF FIRST PATIENT IN BI-1206 PHASE 1 CLINICAL TRIAL FOR THE TREATMENT OF RELAPSED/REFRACTORY NON-HODGKIN'S LYMPHOMA IN CHINAfinance.yahoo.com - September 7 at 8:00 AM Get CASI Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CASI and its competitors with MarketBeat's FREE daily newsletter. Email Address CASI Media Mentions By Week CASI Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CASI News Sentiment▼0.250.51▲Average Medical News Sentiment CASI News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CASI Articles This Week▼10▲CASI Articles Average Week Get CASI Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CASI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Sangamo Therapeutics News Today Solid Biosciences News Today NKGen Biotech News Today aTyr Pharma News Today C4 Therapeutics News Today Ikena Oncology News Today Cidara Therapeutics News Today Adverum Biotechnologies News Today BioAtla News Today Jasper Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:CASI) was last updated on 12/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CASI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.